Clinical evaluations to show that the cPSA test is 7%-22% more specific for prostate cancer than traditional detection tools such as total PSA, leading to fewer false positive results
A lunchtime seminar on the role of complexed prostate specific antigen (cPSA) testing in prostate cancer risk management was hosted by Bayer Diagnostics at the 2003 meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM).
Bernard Croal, clinical senior lecturer in health services research and consultant in clinical biochemistry at Grampian University Hospitals Trust, addressed delegates on the clinical and financial efficacy of the cPSA assay which is available for Bayer's automated immunoassay systems.
He presented study results indicating that use of the assay can lead to a reduction in the number of men undergoing unnecessary prostatic biopsies, thus optimising diagnostic cost-effectiveness.
Rainer Neumann of Bayer's European scientific affairs department cited several other clinical evaluations to show that the Bayer cPSA test is 7%-22% more specific for prostate cancer than traditional detection tools such as total PSA, leading to fewer false positive results.
This has since been confirmed by a major study on the detection of prostate cancer published in the Journal of Urology, November 20031.
